
Lakewood-Amedex Biotherapeutics Faces Nasdaq Delisting Over Bid Price Rule
The company has until Nov. 17, 2026 to request a hearing, and plans to ask for one, which would stay the suspension of trading scheduled for Nov. 19.
Lakewood-Amedex Biotherapeutics Inc. · Nasdaq · Pharmaceutical Preparations

The company has until Nov. 17, 2026 to request a hearing, and plans to ask for one, which would stay the suspension of trading scheduled for Nov. 19.
No open-market insider buying or selling in the Form 4s filed since July 24, 2026.
Delisting notice / failure to meet listing standard · Financial statements and exhibits
AI summary, unreviewedLakewood-Amedex Biotherapeutics receives Nasdaq delisting notice after bid price fell below $1.00 for 30 days and prior reverse split bars compliance period
Entry into a material definitive agreement · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedLakewood-Amedex Biotherapeutics (LABT) redeems all 127,097 Series C preferred shares for $1.27 million in cash, eliminating conversion dilution
Submission of matters to a vote of security holders